Literature DB >> 21506817

Identification of a sporozoite-specific antigen from Toxoplasma gondii.

Dolores Hill1, Cathleen Coss, J P Dubey, Kristen Wroblewski, Mari Sautter, Tiffany Hosten, Claudia Muñoz-Zanzi, Ernest Mui, Shawn Withers, Kenneth Boyer, Gretchen Hermes, Jessica Coyne, Frank Jagdis, Andrew Burnett, Patrick McLeod, Holmes Morton, Donna Robinson, Rima McLeod.   

Abstract

Reduction of risk for human and food animal infection with Toxoplasma gondii is hampered by the lack of epidemiological data documenting the predominant routes of infection (oocyst vs. tissue cyst consumption) in horizontally transmitted toxoplasmosis. Existing serological assays can determine previous exposure to the parasite, but not the route of infection. We have used difference gel electrophoresis, in combination with tandem mass spectroscopy and Western blot, to identify a sporozoite-specific protein (T. gondii embryogenesis-related protein [TgERP]), which elicited antibody and differentiated oocyst- versus tissue cyst-induced infection in pigs and mice. The recombinant protein was selected from a cDNA library constructed from T. gondii sporozoites; this protein was used in Western blots and probed with sera from T. gondii -infected humans. Serum antibody to TgERP was detected in humans within 6-8 mo of initial oocyst-acquired infection. Of 163 individuals in the acute stage of infection (anti- T. gondii IgM detected in sera, or < 30 in the IgG avidity test), 103 (63.2%) had detectable antibodies that reacted with TgERP. Of 176 individuals with unknown infection route and in the chronic stage of infection (no anti- T. gondii IgM detected in sera, or > 30 in the IgG avidity test), antibody to TgERP was detected in 31 (17.6%). None of the 132 uninfected individuals tested had detectable antibody to TgERP. These data suggest that TgERP may be useful in detecting exposure to sporozoites in early T. gondii infection and implicates oocysts as the agent of infection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21506817      PMCID: PMC3684278          DOI: 10.1645/GE-2782.1

Source DB:  PubMed          Journal:  J Parasitol        ISSN: 0022-3395            Impact factor:   1.276


  53 in total

Review 1.  Congenital toxoplasmosis. The Toxoplasmosis Study Group.

Authors:  C N Swisher; K Boyer; R McLeod
Journal:  Semin Pediatr Neurol       Date:  1994-09       Impact factor: 1.636

2.  Detection of Toxoplasma gondii oocysts in drinking water.

Authors:  J Isaac-Renton; W R Bowie; A King; G S Irwin; C S Ong; C P Fung; M O Shokeir; J P Dubey
Journal:  Appl Environ Microbiol       Date:  1998-06       Impact factor: 4.792

3.  Toxoplasma gondii in Vancouver Island cougars (Felis concolor vancouverensis): serology and oocyst shedding.

Authors:  J J Aramini; C Stephen; J P Dubey
Journal:  J Parasitol       Date:  1998-04       Impact factor: 1.276

4.  Potential contamination of drinking water with Toxoplasma gondii oocysts.

Authors:  J J Aramini; C Stephen; J P Dubey; C Engelstoft; H Schwantje; C S Ribble
Journal:  Epidemiol Infect       Date:  1999-04       Impact factor: 2.451

5.  Decreased seroprevalence for Toxoplasma gondii in Seventh Day Adventists in Maryland.

Authors:  M C Roghmann; C T Faulkner; A Lefkowitz; S Patton; J Zimmerman; J G Morris
Journal:  Am J Trop Med Hyg       Date:  1999-05       Impact factor: 2.345

6.  Foodborne outbreaks of human toxoplasmosis.

Authors:  W Y Choi; H W Nam; N H Kwak; W Huh; Y R Kim; M W Kang; S Y Cho; J P Dubey
Journal:  J Infect Dis       Date:  1997-05       Impact factor: 5.226

7.  Antibody responses measured by various serologic tests in pigs orally inoculated with low numbers of Toxoplasma gondii oocysts.

Authors:  J P Dubey; C D Andrews; P Lind; O C Kwok; P Thulliez; J K Lunney
Journal:  Am J Vet Res       Date:  1996-12       Impact factor: 1.156

8.  Toxoplasma gondii in Iowa sows: comparison of antibody titers to isolation of T. gondii by bioassays in mice and cats.

Authors:  J P Dubey; P Thulliez; E C Powell
Journal:  J Parasitol       Date:  1995-02       Impact factor: 1.276

9.  Eye manifestations of congenital toxoplasmosis.

Authors:  M B Mets; E Holfels; K M Boyer; C N Swisher; N Roizen; L Stein; M Stein; J Hopkins; S Withers; D Mack; R Luciano; D Patel; J S Remington; P Meier; R McLeod
Journal:  Am J Ophthalmol       Date:  1996-09       Impact factor: 5.258

10.  Neurologic and developmental outcome in treated congenital toxoplasmosis.

Authors:  N Roizen; C N Swisher; M A Stein; J Hopkins; K M Boyer; E Holfels; M B Mets; L Stein; D Patel; P Meier
Journal:  Pediatrics       Date:  1995-01       Impact factor: 7.124

View more
  47 in total

1.  Oral oocyst-induced mouse model of toxoplasmosis: effect of infection with Toxoplasma gondii strains of different genotypes, dose, and mouse strains (transgenic, out-bred, in-bred) on pathogenesis and mortality.

Authors:  J P Dubey; L R Ferreira; J Martins; Rima McLeod
Journal:  Parasitology       Date:  2011-11-14       Impact factor: 3.234

2.  Positive association between Toxoplasma gondii IgG serointensity and current dysphoria/hopelessness scores in the Old Order Amish: a preliminary study.

Authors:  Abhishek Wadhawan; Aline Dagdag; Allyson Duffy; Melanie L Daue; Kathy A Ryan; Lisa A Brenner; John W Stiller; Toni I Pollin; Maureen W Groer; Xuemei Huang; Christopher A Lowry; Braxton D Mitchell; Teodor T Postolache
Journal:  Pteridines       Date:  2017-11-22       Impact factor: 0.581

3.  Parasites: Kitty carriers.

Authors:  Sarah DeWeerdt
Journal:  Nature       Date:  2017-03-29       Impact factor: 49.962

Review 4.  Toxoplasma gondii-A Gastrointestinal Pathogen Associated with Human Brain Diseases.

Authors:  E G Severance; J Xiao; L Jones-Brando; S Sabunciyan; Y Li; M Pletnikov; E Prandovszky; R Yolken
Journal:  Int Rev Neurobiol       Date:  2016-10-04       Impact factor: 3.230

5.  Toxoplasma gondii seroprevalence in the United States 2009-2010 and comparison with the past two decades.

Authors:  Jeffrey L Jones; Deanna Kruszon-Moran; Hilda N Rivera; Courtney Price; Patricia P Wilkins
Journal:  Am J Trop Med Hyg       Date:  2014-04-07       Impact factor: 2.345

6.  Search for a diagnostic/prognostic biomarker for the brain cancer glioblastoma multiforme by 2D-DIGE-MS technique.

Authors:  Hirendra Nath Banerjee; Kelly Mahaffey; Eilena Riddick; Arnold Banerjee; Niladri Bhowmik; Manomita Patra
Journal:  Mol Cell Biochem       Date:  2012-05-01       Impact factor: 3.396

7.  Unrecognized ingestion of Toxoplasma gondii oocysts leads to congenital toxoplasmosis and causes epidemics in North America.

Authors:  Kenneth Boyer; Dolores Hill; Ernest Mui; Kristen Wroblewski; Theodore Karrison; J P Dubey; Mari Sautter; A Gwendolyn Noble; Shawn Withers; Charles Swisher; Peter Heydemann; Tiffany Hosten; Jane Babiarz; Daniel Lee; Paul Meier; Rima McLeod
Journal:  Clin Infect Dis       Date:  2011-10-21       Impact factor: 9.079

8.  Design, synthesis, and biological activity of diaryl ether inhibitors of Toxoplasma gondii enoyl reductase.

Authors:  Gang Cheng; Stephen P Muench; Ying Zhou; Gustavo A Afanador; Ernest J Mui; Alina Fomovska; Bo Shiun Lai; Sean T Prigge; Stuart Woods; Craig W Roberts; Mark R Hickman; Patty J Lee; Susan E Leed; Jennifer M Auschwitz; David W Rice; Rima McLeod
Journal:  Bioorg Med Chem Lett       Date:  2013-02-13       Impact factor: 2.823

9.  Discrimination of potent inhibitors of Toxoplasma gondii enoyl-acyl carrier protein reductase by a thermal shift assay.

Authors:  Gustavo A Afanador; Stephen P Muench; Martin McPhillie; Alina Fomovska; Arne Schön; Ying Zhou; Gang Cheng; Jozef Stec; Joel S Freundlich; Hong-Ming Shieh; John W Anderson; David P Jacobus; David A Fidock; Alan P Kozikowski; Colin W Fishwick; David W Rice; Ernesto Freire; Rima McLeod; Sean T Prigge
Journal:  Biochemistry       Date:  2013-12-13       Impact factor: 3.162

Review 10.  Molecules to modeling: Toxoplasma gondii oocysts at the human-animal-environment interface.

Authors:  Elizabeth VanWormer; Heather Fritz; Karen Shapiro; Jonna A K Mazet; Patricia A Conrad
Journal:  Comp Immunol Microbiol Infect Dis       Date:  2012-12-04       Impact factor: 2.268

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.